Resistance on Antithrombotic Drugs in Ischemic Heart Disease

Assessment of Aspirin and Clopidogrel Resistance in Ischemic Heart Disease Using Multiplate Function Analyser and it's Correlation With Major Adverse Cardiac Events

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT00742430

Enrollment

141

Registered

2008-08-27

Start date

2009-02-28

Completion date

2011-08-31

Last updated

2012-02-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary Artery Disease

Keywords

aspirin resistance, coronary artery disease, clopidogrel resistance, major adverse cardiac events, multiplate platelet function analyser, percutaneous coronary intervention

Brief summary

The purpose of this study is to determine whether aspirin and clopidogrel resistance measured with Multiplate function analyser has a good correlation with incidence of major adverse cardiac events in patients with coronary artery disease (CAD).

Detailed description

Our plan is to enroll 180 patients with diagnosed CAD who electively undergo percutaneous coronary intervention (PCI). Blood samples will be taken just before the procedure and one day after the procedure and analysed on Multiplate function analyser. Assessing aspirin and clopidogrel resistance incidence using Multiplate platelet function analyzer we will also try to find resistance correlation with the incidence of major adverse cardiac events in a one year follow up.

Interventions

PROCEDUREPCI

percutaneous coronary intervention in stable coronary artery disease

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

* Elective PCI * \> 7 days on aspirin 100mg therapy before the intervention * \> 7 days on clopidogrel 75mg therapy before the intervention

Exclusion criteria

* Loading dose of clopidogrel * \< 7 days on aspirin therapy before the intervention * Myocardial infarction less than 30 days before the intervention * Cerebrovascular incident less that three months before the intervention * Haemorrhagic diathesis * Trc \< 100 * Htc \< 30% * Creatinine \> 140

Design outcomes

Primary

Measure	Time frame
Major adverse coronary event	12 months

Countries

Croatia

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026